We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BerGenBio Earns FDA Fast Track Status for NSCLC Combination
BerGenBio Earns FDA Fast Track Status for NSCLC Combination
The FDA has granted Fast Track designation to BerGenBio’s Bemcentinib in combination with an anti-PD-(L)1 therapy for patients with AXL-positive advanced or metastatic nonsmall-cell lung cancer (NSCLC).